MiMedx Group, Inc. (MDXG)
NASDAQ (CM) NASDAQ (CM) Primary Summary
MiMedx Group Q2 Earnings Call Highlights
MiMedx Group NASDAQ: MDXG said it has agreed to acquire Sanara MedTech in a transaction valued at $35 per Sanara share, a deal the company expects to close by the end of 2026. The announcement accompanied MiMedx's second-quarter results, which showed sequential improvement in its wound-care business and continued growth in surgical sales.
Is the Options Market Predicting a Spike in MiMedx Group Stock?
Investors need to pay close attention to MDXG stock based on the movements in the options market lately.
MiMedx Group, Inc. (MDXG) Q1 2026 Earnings Call Transcript
MiMedx Group, Inc. (MDXG) Q1 2026 Earnings Call Transcript
MiMedx Group, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 320 | $2,019.55 | $1,337.6 | -$681.95 | -33.77% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 261,721 | $1.64M | $1.14M | -$507,472.49 | -30.88% |
| BG Bart Gancher Intech Investment Management LLC | 29,516 | $246,135.58 | $128,099.44 | -$118,036.14 | -47.96% |
 Private Capital Private Capital Management | 19,591 | $75,425 | $83,653.57 | $8,228.57 | 10.91% |
 Point72 Asset Management LP Point72 Asset Management LP | 123,557 | $836,480.78 | $527,588.39 | -$308,892.39 | -36.93% |
MiMedx Group, Inc. (MDXG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has MiMedx Group, Inc. ever had a stock split?
MiMedx Group, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Joseph H. Capper CEO | NASDAQ (CM) Exchange | 602496101 CUSIP |
| US Country | 808 Employees | - Last Dividend | 2 Apr 2008 Last Split | 22 Aug 2007 IPO Date |
Overview
MiMedx Group, Inc. is a pioneering company focused on the development and distribution of placental tissue allografts across various healthcare sectors. Founded in 2011 and headquartered in Marietta, Georgia, the company stands out for its innovative processing of human placental tissues. By using its patented and proprietary PURION process, MiMedx succeeds in producing allografts that preserve the essential biological properties and regulatory proteins of the tissue. This unique processing method incorporates aseptic techniques along with terminal sterilization to ensure safety and efficacy. The company's groundbreaking work primarily benefits the wound care, burn treatment, and surgical recovery sectors within healthcare. Marketed primarily in the United States, its products reach end-users through a strategic blend of direct sales efforts and partnerships with independent sales agents and distributors.
Products and Services
MiMedx Group, Inc. has developed an impressive portfolio of products leveraging the innate healing properties of placental tissues. These include:
- EpiFix: A flagship product, EpiFix is an allograft barrier membrane designed for the treatment of chronic wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. It represents a prime example of how MiMedx applies its proprietary technology to address complex medical challenges in wound care.
- AmnioFix: Serving as a protective barrier allograft, AmnioFix consists of dehydrated human amnion/chorion membrane. It is primarily used in surgical recovery applications, offering support for soft tissue regeneration and repair. This product underscores the company's commitment to enhancing post-surgical healing processes and outcomes.
- EpiCord & AmnioCord: Both EpiCord and AmnioCord are dehydrated human umbilical cord allografts curated to foster a conducive healing environment. These products are ingeniously designed for use in advanced wound care and surgical recovery scenarios. By providing critical support to the body's own healing mechanisms, these allografts exemplify the innovative approach MiMedx takes towards contributing to healthcare solutions.
